The Boston-based startup is developing what executives hope will be more effective treatments for depression, anxiety, and ...

Boston-based Seaport Therapeutics closed $225 million in new capital, bringing its total funding to $325 million.

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Earlier this year, BMY completed a $14 billion acquisition of Karuna Therapeutics, gaining access to its experimental ...

Two Key Executive Hires for Organizational Capabilities and GrowthCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos ...

BioSpace has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision ...

Click Therapeutics, Croium, Emalex, Idorsia, Karuna, Lumos Labs, Medgenics, Neurocrine, NLS Pharma, Sirtsei, and Sumitomo.

The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a pivotal moment in the treatment of schizophrenia. KarXT, an oral dual M1/M4 ...